Highest-materiality recent filing
Waters Q1 revenue $1.267B beats guidance; raises FY2026 adjusted EPS outlook to $14.40-$14.60
Total reported revenue of $1.267B exceeded guidance by $56M; GAAP EPS ($0.87) due to acquisition charges, Adjusted EPS $2.70 (+20% YoY).
Waters subsidiary issues $3.5B in senior notes across five tranches to repay DDTL
Issuer Augusta SpinCo completed offering of $3.5B senior notes: 4.321% due 2027, 4.398% 2029, 4.656% 2031, 4.945% 2033, 5.245% 2036.
Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M
Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.
Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).
Waters completes $4B combination with BD's Biosciences & Diagnostic Solutions; forms four divisions
Consummated spin-off and merger of BD's Biosciences & Diagnostic Solutions; BD shareholders received ~0.135 Waters shares per BD share, owning 39.2% of combined company.
Waters shareholders approve BD Biosciences combination; close expected Feb 9, 2026
Approximately 99% of shares present at special meeting voted to approve share issuance for BD Biosciences deal.
Waters supplements merger proxy after two stockholder lawsuits alleging omissions
Two lawsuits filed in NY Supreme Court (Carroll, Clark) claim proxy omits material information; demand letters also received.
Waters Q3 sales $800M (+8% YoY), non-GAAP EPS $3.40 (+16%), raises FY guidance
Sales $800M, +8% as reported and constant currency, above guidance.
Waters Q2 sales $771M (+9% reported, +8% CC); GAAP EPS $2.47, non-GAAP $2.95; raises FY guidance
Sales $771M, up 9% reported and 8% constant currency vs $709M prior year.
Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal
Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.
Waters to acquire BD's Biosciences & Diagnostic Solutions via Reverse Morris Trust
Waters shareholders to own ~60.8% and former SpinCo shareholders ~39.2% of combined company post-merger.
Waters Q4 sales $873M beat guidance; non-GAAP EPS $4.10 up 13% YoY; FY2025 EPS guide $12.70-$13.00
Q4 sales $873M, +6% reported / +8% constant currency; exceeded high-end of guidance range.
Waters Q3 sales $740M (+4% YoY); GAAP EPS $2.71, non-GAAP $2.93; raises FY guidance
Sales $740M (+4% as reported and constant currency); GAAP EPS $2.71, non-GAAP EPS $2.93, beating guidance.
Waters Q4 2023 sales $819M (-4.5%); FY guidance organic growth -0.5% to +1.5%
Q4 GAAP EPS $3.65, non-GAAP $3.62 (at high end of guidance); YoY decline from $3.84.
On August 13, 2024, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Heather Knight to the Board, effective August 14, 2024, to fill the vacancy so created.
Max materiality 0.90 · Median 0.65 · Most common event earnings